within Pharmacolibrary.Drugs.ATC.A;

model A01AB17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.99,
    Cl             = 3.9999999999999996e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.041,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015550000000000001,
    Tlag           = 840
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A01AB17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Metronidazole is a nitroimidazole antibiotic and antiprotozoal medication used to treat various infections caused by anaerobic bacteria and protozoa, including bacterial vaginosis, trichomoniasis, giardiasis, amebiasis, and certain intra-abdominal and dental infections. It is widely approved and used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Lamp, KC, et al., &amp; Lacy, MK (1999). Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. <i>Clinical pharmacokinetics</i> 36(5) 353–373. DOI:<a href=\"https://doi.org/10.2165/00003088-199936050-00004\">10.2165/00003088-199936050-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10384859/\">https://pubmed.ncbi.nlm.nih.gov/10384859</a></p></li><li><p>Louie, TJ, et al., &amp; Shue, YK (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. <i>The New England journal of medicine</i> 364(5) 422–431. DOI:<a href=\"https://doi.org/10.1056/NEJMoa0910812\">10.1056/NEJMoa0910812</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21288078/\">https://pubmed.ncbi.nlm.nih.gov/21288078</a></p></li><li><p>Mimura, Y, et al., &amp; Kuragano, T (2020). The pharmacokinetics of oral metronidazole in patients with metronidazole-induced encephalopathy undergoing maintenance hemodialysis. <i>Hemodialysis international. International Symposium on Home Hemodialysis</i> 24(4) 528–533. DOI:<a href=\"https://doi.org/10.1111/hdi.12857\">10.1111/hdi.12857</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33460224/\">https://pubmed.ncbi.nlm.nih.gov/33460224</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A01AB17;
